QUiPP App v.2预测模型的开发与验证:用于预测无症状高危女性早产的工具
本研究基于13个英国早产诊所的前瞻性数据,开发并验证了QUiPP App v.2预测模型,用于无症状高危女性自发性早产(sPTB)的预测。训练集1803例女性(3878次就诊),验证集904例(1400次就诊)。三种算法(宫颈长度、定量胎儿纤连蛋白或两者联合)在预测<30、<34、<37周及检测后1、2、4周内sPTB时AUC在0.68-0.90之间,差异无统计学意义。校准显示4周内预测与观察率无显著差异,但22+0至25+6周宫颈长度测量略高估风险。
要点
- QUiPP App v.2基于宫颈长度和/或定量胎儿纤连蛋白,可个体化预测无症状高危女性早产风险。
- 三种算法预测sPTB的AUC在0.68-0.90之间,差异无统计学意义。
- 校准显示4周内预测与观察率无显著差异,但22+0至25+6周宫颈长度测量略高估风险。
核心结论
- QUiPP App v.2是基于生物标志物、症状和统计算法组合的高精度sPTB预测工具,可可靠用于与患者沟通sPTB风险。
- 虽需进一步工作确定其在识别需要预防性干预女性中的作用,但它是规划高危女性随访或住院的可靠便捷筛查工具。
研究设计与样本
- 前瞻性二次分析,数据来自13个英国早产诊所招募的无症状sPTB高危女性。
- 训练集1803例女性(3878次就诊),验证集904例女性(1400次就诊)。
- 女性在孕18+0至36+6周间每2-4周接受纵向qfFN检测和/或经阴道超声CL测量。
主要发现
- 三种算法预测<30、<34、<37周及检测后1、2、4周内sPTB的AUC:qfFN联合CL为0.75-0.90,单用qfFN为0.68-0.90,单用CL为0.71-0.87。
- 三种算法间差异无统计学意义。
- 校准显示4周内预测与观察sPTB率无显著差异,但22+0至25+6周使用CL测量略高估风险。
关键数值与推荐
- qfFN联合CL预测sPTB的AUC为0.75-0.90。
- 单用qfFN预测sPTB的AUC为0.68-0.90。
- 单用CL预测sPTB的AUC为0.71-0.87。
临床怎么用
- QUiPP App v.2可可靠用于与患者沟通sPTB风险。
- 它是规划高危女性随访或住院的可靠便捷筛查工具。
- 作者指出需进一步工作确定其在识别需要预防性干预女性中的作用。
局限性
- 需进一步工作确定其在识别需要预防性干预女性中的作用。
- 22+0至25+6周使用CL测量略高估风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Accurate mid-pregnancy prediction of spontaneous preterm birth (sPTB) is essential to ensure appropriate surveillance of high-risk women. Advancing the QUiPP App prototype, QUiPP App v.2 aimed to provide individualized risk of delivery based on cervical length (CL), quantitative fetal fibronectin (qfFN) or both tests combined, taking into account further risk factors, such as multiple pregnancy. Here we report development of the QUiPP App v.2 predictive models for use in asymptomatic high-risk women, and validation using a distinct dataset in order to confirm the accuracy and transportability of the QUiPP App, overall and within specific clinically relevant time frames. METHODS: This was a prospective secondary analysis of data of asymptomatic women at high risk of sPTB recruited in 13 UK preterm birth clinics. Women were offered longitudinal qfFN testing every 2-4 weeks and/or transvaginal ultrasound CL measurement between 18 + 0 and 36 + 6 weeks' gestation. A total of 1803 women (3878 visits) were included in the training set and 904 women (1400 visits) in the validation set. Prediction models were created based on the training set for use in three groups: patients with risk factors for sPTB and CL measurement alone, with risk factors for sPTB and qfFN measurement alone, and those with risk factors for sPTB and both CL and qfFN measurements. Survival analysis was used to identify the significant predictors of sPTB, and parametric structures for survival models were compared and the best selected. The estimated overall probability of delivery before six clinically important time points (< 30, < 34 and < 37 weeks' gestation and within 1, 2 and 4 weeks after testing) was calculated for each woman and analyzed as a predictive test for the actual occurrence of each event. This allowed receiver-operating-characteristics curves to be plotted, and areas under the curve (AUC) to be calculated. Calibration was performed to measure the agreement between expected and observed outcomes. RESULTS: All three algorithms demonstrated high accuracy for the prediction of sPTB at < 30, < 34 and < 37 weeks' gestation and within 1, 2 and 4 weeks of testing, with AUCs between 0.75 and 0.90 for the use of qfFN and CL combined, between 0.68 and 0.90 for qfFN alone, and between 0.71 and 0.87 for CL alone. The differences between the three algorithms were not statistically significant. Calibration confirmed no significant differences between expected and observed rates of sPTB within 4 weeks and a slight overestimation of risk with the use of CL measurement between 22 + 0 and 25 + 6 weeks' gestation. CONCLUSIONS: The QUiPP App v.2 is a highly accurate prediction tool for sPTB that is based on a unique combination of biomarkers, symptoms and statistical algorithms. It can be used reliably in the context of communicating to patients the risk of sPTB. Whilst further work is required to determine its role in identifying women requiring prophylactic interventions, it is a reliable and convenient screening tool for planning follow-up or hospitalization for high-risk women. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Watson HA, Seed PT, Carter J, et al. Development and validation of predictive models for QUiPP App v.2: tool for predicting preterm birth in asymptomatic high-risk women. Ultrasound Obstet Gynecol. 2020. PMID: 31325332. doi:10.1002/uog.20401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。